Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

Abstract Background To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods We reviewed the medical re...

Full description

Bibliographic Details
Main Authors: Liancheng Fan, Baijun Dong, Chenfei Chi, Yanqing Wang, Yiming Gong, Jianjun Sha, Jiahua Pan, Xun Shangguan, Yiran Huang, Lixin Zhou, Wei Xue
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Urology
Subjects:
Abiraterone
Metastatic castration-resistant prostate cancer
Chemotherapy-naive
Response to previous therapy
Online Access:http://link.springer.com/article/10.1186/s12894-018-0416-6

Internet

http://link.springer.com/article/10.1186/s12894-018-0416-6

Similar Items